ADAP Research | Milton Maxwell

ADAP

Adaptimmune Therapeutics plc

0.0549

+0.0549+0%

Oct 27, 4:00:00 PM EDT

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

14.55M

P/E (TTM)

Basic EPS (TTM)

-0.66

Dividend Yield

Recent Filings

8-K

Voluntary Nasdaq delisting announced

10/20/25Oct 20, 2025

Adaptimmune Therapeutics voluntarily delists its ADSs from Nasdaq, with trading suspension set for October 27, 2025, after filing Form 25 around October 28. The board aims to slash public reporting costs post-July asset sale to US WorldMeds, freeing resources for PRAME and CD70 programs. Delisting burdens outweigh benefits. OTC Pink quotation uncertain.

8-K

Nasdaq bid price extension granted

9/26/25Sep 26, 2025

Adaptimmune Therapeutics received Nasdaq Panel notice on September 22, 2025, granting an exception until December 1, 2025, to lift its ADAP ADS bid price above $1.00 per share. Compliance hinges on market performance. Delisting looms if unmet.

8-K

Nasdaq compliance warning issued

9/12/25Sep 12, 2025

Adaptimmune Therapeutics received a Nasdaq notice on September 11, 2025, for MVLS below $35.0 million over 32 business days, plus failing equity and income standards. Trading continues uninterrupted, but compliance is due by March 10, 2026, via ten consecutive days above the threshold. No assurance of success. Delisting looms otherwise.

8-K

New CFO consulting hire

9/8/25Sep 8, 2025

Adaptimmune Therapeutics tapped Christopher Hill as CFO via a consulting agreement with CJH Financial, effective September 10, 2025, through December 31, 2026. Hill, with over a decade in life sciences finance, steps down from Istesso Limited on September 9; compensation runs £2,200 per day, capped at £500,000 initially, with no bonuses or options. Flexible contractor setup aids oversight of SEC filings and clinical trials. Termination possible on 30 days' notice for breach.

8-K

CFO, Supply Officer exits

8/29/25Aug 29, 2025

Adaptimmune Therapeutics updated termination terms for CFO Gavin Wood, ending September 9, 2025, with 12 months base salary plus discretionary pro rata bonus of ~$156K and continued option vesting. Chief Patient Supply Officer John Lunger exits August 31, 2025, receiving $472K severance and $20K COBRA lump sum. Both get 12-month option exercise windows. Redundancy cuts signal restructuring.

About

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

CEO

Mr. Adrian G. Rawcliffe

IPO

5/6/2015

Website

https://www.adaptimmune.com

Employees

506

Sector

Healthcare

Industry

Biotechnology